LIGANDAL
Ligandal is a regenerative medicine and pandemic defense biotechnology company. Our current lead candidate, SARS-BLOCK™, is designed as an "antidote-vaccine" against the virus that causes COVID-19.
We use supercomputing and AI to develop next-generation medicine, bringing you nearly a decade of experience in developing peptide-based technologies for gene therapy, gene editing, regenerative medicine, immunotherapy, and advanced antidote-vaccine technologies.
We use supercomputing and AI to develop next-generation medicine, bringing you nearly a decade of experience in developing peptide-based technologies for gene therapy, gene editing, regenerative medicine, immunotherapy, and advanced antidote-vaccine technologies.
SEE OUR PUBLICATION: PEPTIDE ANTIDOTES TO SARS-COV-2 (COVID-19)
